BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21957230)

  • 1. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
    Nick AM; Stone RL; Armaiz-Pena G; Ozpolat B; Tekedereli I; Graybill WS; Landen CN; Villares G; Vivas-Mejia P; Bottsford-Miller J; Kim HS; Lee JS; Kim SM; Baggerly KA; Ram PT; Deavers MT; Coleman RL; Lopez-Berestein G; Sood AK
    J Natl Cancer Inst; 2011 Nov; 103(21):1596-612. PubMed ID: 21957230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
    Merritt WM; Lin YG; Spannuth WA; Fletcher MS; Kamat AA; Han LY; Landen CN; Jennings N; De Geest K; Langley RR; Villares G; Sanguino A; Lutgendorf SK; Lopez-Berestein G; Bar-Eli MM; Sood AK
    J Natl Cancer Inst; 2008 Mar; 100(5):359-72. PubMed ID: 18314475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional roles of Src and Fgr in ovarian carcinoma.
    Kim HS; Han HD; Armaiz-Pena GN; Stone RL; Nam EJ; Lee JW; Shahzad MM; Nick AM; Lee SJ; Roh JW; Nishimura M; Mangala LS; Bottsford-Miller J; Gallick GE; Lopez-Berestein G; Sood AK
    Clin Cancer Res; 2011 Apr; 17(7):1713-21. PubMed ID: 21300758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
    Halder J; Kamat AA; Landen CN; Han LY; Lutgendorf SK; Lin YG; Merritt WM; Jennings NB; Chavez-Reyes A; Coleman RL; Gershenson DM; Schmandt R; Cole SW; Lopez-Berestein G; Sood AK
    Clin Cancer Res; 2006 Aug; 12(16):4916-24. PubMed ID: 16914580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.
    Halder J; Landen CN; Lutgendorf SK; Li Y; Jennings NB; Fan D; Nelkin GM; Schmandt R; Schaller MD; Sood AK
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8829-36. PubMed ID: 16361572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of EphA2 and FAK in ovarian carcinoma.
    Shahzad MM; Lu C; Lee JW; Stone RL; Mitra R; Mangala LS; Lu Y; Baggerly KA; Danes CG; Nick AM; Halder J; Kim HS; Vivas-Mejia P; Landen CN; Lopez-Berestein G; Coleman RL; Sood AK
    Cancer Biol Ther; 2009 Jun; 8(11):1027-34. PubMed ID: 19395869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
    Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
    J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of forkhead box O3 transcription is involved in C2-ceramide induced apoptosis and autophagy in ovarian cancer cells in vitro.
    Jin Z; Zheng L; Xin X; Li Y; Hua T; Wu T; Wang H
    Mol Med Rep; 2014 Dec; 10(6):3099-105. PubMed ID: 25323477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.
    Vivas-Mejia PE; Rodriguez-Aguayo C; Han HD; Shahzad MM; Valiyeva F; Shibayama M; Chavez-Reyes A; Sood AK; Lopez-Berestein G
    Clin Cancer Res; 2011 Jun; 17(11):3716-26. PubMed ID: 21512144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas.
    Katagiri H; Nakayama K; Razia S; Nakamura K; Sato E; Ishibashi T; Ishikawa M; Iida K; Ishikawa N; Otsuki Y; Nakayama S; Kyo S
    Int J Oncol; 2015 Dec; 47(6):2037-44. PubMed ID: 26458502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
    Lee JW; Han HD; Shahzad MM; Kim SW; Mangala LS; Nick AM; Lu C; Langley RR; Schmandt R; Kim HS; Mao S; Gooya J; Fazenbaker C; Jackson D; Tice DA; Landen CN; Coleman RL; Sood AK
    J Natl Cancer Inst; 2009 Sep; 101(17):1193-205. PubMed ID: 19641174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beclin-1 expression is retained in high-grade serous ovarian cancer yet is not essential for autophagy induction in vitro.
    Correa RJ; Valdes YR; Shepherd TG; DiMattia GE
    J Ovarian Res; 2015 Aug; 8():52. PubMed ID: 26239434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
    Halder J; Lin YG; Merritt WM; Spannuth WA; Nick AM; Honda T; Kamat AA; Han LY; Kim TJ; Lu C; Tari AM; Bornmann W; Fernandez A; Lopez-Berestein G; Sood AK
    Cancer Res; 2007 Nov; 67(22):10976-83. PubMed ID: 18006843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.
    Lin YG; Immaneni A; Merritt WM; Mangala LS; Kim SW; Shahzad MM; Tsang YT; Armaiz-Pena GN; Lu C; Kamat AA; Han LY; Spannuth WA; Nick AM; Landen CN; Wong KK; Gray MJ; Coleman RL; Bodurka DC; Brinkley WR; Sood AK
    Clin Cancer Res; 2008 Sep; 14(17):5437-46. PubMed ID: 18765535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
    Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK
    Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
    Lee YY; Jeon HK; Hong JE; Cho YJ; Ryu JY; Choi JJ; Lee SH; Yoon G; Kim WY; Do IG; Kim MK; Kim TJ; Choi CH; Lee JW; Bae DS; Kim BG
    Oncotarget; 2015 Oct; 6(33):35040-50. PubMed ID: 26418900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of small interfering RNA inhibit Class I phosphoinositide 3-kinase on human gastric cancer cells.
    Zhu BS; Yu LY; Zhao K; Wu YY; Cheng XL; Wu Y; Zhong FY; Gong W; Chen Q; Xing CG
    World J Gastroenterol; 2013 Mar; 19(11):1760-9. PubMed ID: 23555164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of AMPK-dependent autophagy enhances in vitro antiglioma effect of simvastatin.
    Misirkic M; Janjetovic K; Vucicevic L; Tovilovic G; Ristic B; Vilimanovich U; Harhaji-Trajkovic L; Sumarac-Dumanovic M; Micic D; Bumbasirevic V; Trajkovic V
    Pharmacol Res; 2012 Jan; 65(1):111-9. PubMed ID: 21871960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.